Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
First Claim
1. A method of treating a gastrointestinal condition in a subject, said method comprising:
- selecting a subject in need of treatment of the gastrointestinal condition, and administering a composition comprising one or more branched chain fatty acids to the subject under conditions effective to treat the gastrointestinal condition in the subject, wherein the one or more branched fatty acids is a C11 to C26 alkyl substituted branched chain fatty acid or mixtures thereof, wherein the composition comprises at least 2 wt % of the one or more branched chain fatty acids, wherein the gastrointestinal condition is associated with inflammation, and wherein the composition is not milk or colostrum.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. In general, branched chain fatty acids, in accordance with the present invention, may be non-esterified fatty acids or covalently linked to a lipid, including wax esters, sterol esters, triacylglycerols, or any other lipid-related molecular species, natural or artificial. The branched chain fatty acid can be a C11 to C26 branched chain fatty acid and mixtures thereof.
-
Citations
48 Claims
-
1. A method of treating a gastrointestinal condition in a subject, said method comprising:
- selecting a subject in need of treatment of the gastrointestinal condition, and administering a composition comprising one or more branched chain fatty acids to the subject under conditions effective to treat the gastrointestinal condition in the subject, wherein the one or more branched fatty acids is a C11 to C26 alkyl substituted branched chain fatty acid or mixtures thereof, wherein the composition comprises at least 2 wt % of the one or more branched chain fatty acids, wherein the gastrointestinal condition is associated with inflammation, and wherein the composition is not milk or colostrum.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
25. A method of treatment or prevention of necrotizing enterocolitis in a subject, said method comprising:
- selecting a subject in need of prevention or treatment of necrotizing enterocolitis, and administering a composition comprising one or more branched chain fatty acids to the subject under conditions effective to prevent or treat the necrotizing enterocolitis in the subject, wherein the one or more branched chain fatty acid is a C11 to C26 alkyl-substituted branched chain fatty acid or mixtures thereof, wherein the composition comprises at least 2 wt % of the one or more branched chain fatty acids and wherein the composition is not milk or colostrum.
-
26. A method of preventing a gastrointestinal condition in a subject, said method comprising:
- selecting a subject in need of prevention of the gastrointestinal condition, and administering a composition comprising one or more branched chain fatty acids to the subject under conditions effective to prevent the gastrointestinal condition in the subject, wherein the one or more branched chain fatty acid is a C11 to C26 alkyl-substituted branched chain fatty acid or mixtures thereof, wherein the composition comprises at least 2 wt % of the one or more branched chain fatty acids, wherein the gastrointestinal condition is necrotizing enterocolitis or inflammatory bowel disease, and wherein the composition is not milk or colostrum.
- View Dependent Claims (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
Specification